Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Humedics Receives Patent on Method for Quantitative Liver Function Analysis

Published: Tuesday, April 16, 2013
Last Updated: Tuesday, April 16, 2013
Bookmark and Share
Patent is a milestone for further commercialization of the LiMAx test.

Humedics GmbH has announced that another key patent protecting Humedics’ proprietary technology has been granted by Australian authorities.

The Australian patent AU20062664108 covers an analysis method for determining a functional parameter of an organ using a 13C labeled methacetin solution.

“This patent is a milestone for the commercialization of our LiMAx test and the corresponding FLIP device”, says Prof. Dr. Karsten Heyne, co-founder of Humedics GmbH.

Prof. Heyne continued, “We receive so much positive feedback on this test system from clinical users and, from a company perspective, it is great that the essential part of our proprietary technology is protected by now.”

The underlying principle of the test involves the following steps: At first, a13Cmethacetin solution is administered intravenously. Methacetin is metabolized in the liver to paracetamol and 13CO2 and the latter is exhaled in the breath.

The exhaled air is collected via a respiratory mask. Subsequent measurement of 13CO2 in a detection device provides a quantitative determination of the liver capacity and thus the liver function.

“Liver surgery and liver transplantation often are very serious interventions” says Dr. Martin Stockmann, co-founder of Humedics GmbH and co-owner of the mentioned patent. “It is therefore a high medical need to determine liver function prior to this kind of interventions to better assess the prognosis and also after interventions to monitor recovery.”

The LiMAx test fulfills these requirements. Liver diagnostic tests available on the market so far are of limited use for this purpose and do not provide a quantitative liver function analysis.

The LiMAx test is a bedside test that can be performed prior, during and subsequent to surgery. And the liver surgeon at Charité - Universitätsmedizin Berlin adds: “In liver surgery the LiMAx test provides added value to make correct therapeutic decisions and to improve therapy control.”

The recently granted patent adds to Humedics’ portfolio of pending and granted patents that secures the economic utilization of the company’s products.

A previously granted patent covers the measurement device and a method for analyzing a sample gas by infrared absorption (German Patent No 102009055320) and thus Humedics’ FLIP device for the measurement of exhaled air.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Humedics Receives ISO 13485 Certification
Milestone for market entry of LiMAx test for liver function diagnostics.
Tuesday, August 11, 2015
Humedics Closes 6.3 Million€ Financing Round
Cash inflow enables for commercialization of the LiMAx test.
Friday, November 14, 2014
Humedics Co-founder Martin Stockmann Awarded with Von-Langenbeck Prize
Award ceremony at the annual conference of the German Society of Surgery.
Tuesday, July 16, 2013
Humedics Starts LiMAx Phase III Trial on Liver Function Analysis for Severe Liver Surgery
First patients being included directly after study initiation in Berlin and Jena.
Monday, March 04, 2013
Humedics Appoints Erwin de Buijzer as Managing Director for Marketing and Sales
Erwin de Buijzer support further development and strategic positioning of the company.
Monday, May 07, 2012
Scientific News
‘Mutation-Tracking’ Blood Test for Breast Cancer
Scientists have developed a blood test for breast cancer able to identify which patients will suffer a relapse after treatment, months before tumours are visible on hospital scans.
Common ‘Heart Attack’ Blood Test May Predict Future Hypertension
Small rises in troponin levels may have value as markers for subclinical heart damage and high blood pressure.
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
'Fountain of Youth' Protein Points to Possible Human Health Benefit
Patients with higher blood levels of growth factor have lower risk of cardiovascular problems.
Signature of Microbiomes Linked to Schizophrenia
Studying microbiomes in throat may help identify causes and treatments of brain disorder.
Imaging Software Could Speed Breast Cancer Diagnosis
Technology could improve access to diagnostic services in developing countries.
The Changing Tides of the In Vitro Diagnostics Market
With the increasing focus in personalized medicine, diagnostics plays a crucial role in patient monitoring.
Data Mining DNA For Polycystic Ovary Syndrome Genes
A new Northwestern Medicine genome-wide association study of PCOS – the first of its kind to focus on women of European ancestry – has provided important new insights into the underlying biology of the disorder.
Algorithm Interprets Breathing Difficulties to Aid in Medical Care
Researchers from North Carolina State University have developed an efficient algorithm that can interpret the wheezing of patients with breathing difficulties to give medical providers information about what’s happening in the lungs.
Researchers Develop qPCR Prognosis Test for NSCLC Patients
A nine-gene molecular prognostic index (MPI) for patients with early-stage non-small cell lung cancer (NSCLC) was able to provide accurate survival stratification and could potentially inform the use of adjuvant therapy in patients struggling with the disease.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!